stockportfolio.pro
Stocks / GH vs JAZZ
GH vs JAZZ
Guardant Health, Inc. and Jazz Pharmaceuticals plc side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Guardant Health, Inc. (GH) | Jazz Pharmaceuticals plc (JAZZ) | |
|---|---|---|
| Market cap | $17.4B | $14.4B |
| Revenue (latest FY) | $982.02M | $4.27B |
| Net income (latest FY) | $-416.28M | $-356.15M |
| Revenue growth (5y CAGR) | 27.9% | 12.5% |
| Net margin | -42.4% | -8.3% |
| Return on equity | 419.2% | -8.2% |
| P/E ratio | — | 2080.5 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 7 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open GH — free Open JAZZ — freeFrequently asked questions
Which is bigger, GH or JAZZ?
Guardant Health, Inc. is larger by market capitalization — $17.4B versus $14.4B.
Which grows faster, GH or JAZZ?
Over the last five fiscal years, Guardant Health, Inc. grew revenue faster — 27.9%/yr versus 12.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.